Literature DB >> 15271229

An evaluation of 2 new devices for nasal high-flow gas therapy.

Jonathan B Waugh1, Wesley M Granger.   

Abstract

BACKGROUND: The traditional nasal cannula with bubble humidifier is limited to a maximum flow of 6 L/min to minimize the risk of complications. We conducted a bench study of 2 new Food and Drug Administration-approved nasal cannula/humidifier products designed to deliver at flows> 6 L/min.
METHODS: Using a digital psychrometer we measured the relative humidity and temperature of delivered gas from each device, at 5 L/min increments over the specified functional high-flow range.
RESULTS: The Salter Labs unit achieved 72.5-78.7% relative humidity (5-15 L/min range) at ambient temperature (21-23 degrees C). The Vapotherm device achieved 99.9% relative humidity at a temperature setting of 37 degrees C (5-40 L/min).
CONCLUSIONS: Both devices meet minimum humidification standards and offer practical new treatment options. The patient-selection criteria are primarily the severity of the patient's condition and cost.

Entities:  

Mesh:

Year:  2004        PMID: 15271229

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  8 in total

1.  Flash pulmonary edema in a post arterial switch operation - High flow oxygen as a treatment modality.

Authors:  Jamuna Kumar; Rajesh Hegde; Sunita Maheshwari; Shekar Rao
Journal:  Ann Pediatr Cardiol       Date:  2009-07

Review 2.  Applications of Nasal High-Flow Oxygen Therapy in Critically ill Adult Patients.

Authors:  Jahan Porhomayon; Ali A El-Solh; Leili Pourafkari; Philippe Jaoude; Nader D Nader
Journal:  Lung       Date:  2016-05-03       Impact factor: 2.584

3.  Heated humidified high-flow nasal cannula versus low-flow nasal cannula as weaning mode from nasal CPAP in infants ≤28 weeks of gestation.

Authors:  Jose Ramon Fernandez-Alvarez; Rashmi Shreyans Gandhi; Philip Amess; Liam Mahoney; Ryan Watkins; Heike Rabe
Journal:  Eur J Pediatr       Date:  2013-08-14       Impact factor: 3.183

4.  High-flow nasal interface improves oxygenation in patients undergoing bronchoscopy.

Authors:  Umberto Lucangelo; Fabio Giuseppe Vassallo; Emanuele Marras; Massimo Ferluga; Elena Beziza; Lucia Comuzzi; Giorgio Berlot; Walter Araujo Zin
Journal:  Crit Care Res Pract       Date:  2012-05-20

5.  A multicentre, randomised controlled, non-inferiority trial, comparing high flow therapy with nasal continuous positive airway pressure as primary support for preterm infants with respiratory distress (the HIPSTER trial): study protocol.

Authors:  Calum T Roberts; Louise S Owen; Brett J Manley; Susan M Donath; Peter G Davis
Journal:  BMJ Open       Date:  2015-06-24       Impact factor: 2.692

6.  A comparison of two interventions for HHHFNC in preterm infants weighing 1,000 to 1,500 g in the recovery period of newborn RDS.

Authors:  Alireza Sadeghnia; Zohre Badiei; Hassan Talakesh
Journal:  Adv Biomed Res       Date:  2014-08-19

7.  High-flow nasal cannula therapy for initial oxygen administration in acute hypercapnic respiratory failure: study protocol of randomised controlled unblinded trial.

Authors:  Asem Alnajada; Bronagh Blackwood; Abdulmajeed Mobrad; Adeel Akhtar; Murali Shyamsundar
Journal:  BMJ Open Respir Res       Date:  2021-01

8.  A multicomponent oxygen delivery strategy for COVID-19 patients in a step-down intensive care unit: A case series.

Authors:  Fanny Giron; Swathi Rao; Natalie Tapaskar
Journal:  Respir Med Case Rep       Date:  2020-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.